BRIDGE Stroke did not demonstrate any significant difference between interventions and controls on their primary composite adherence outcome, which was the sum of antithrombotic use, deep vein thrombosis prophylaxis use, tissue plasminogen activator (tPA) door to needle time, dysphagia screening performed, rehabilitation assessment performed, statin prescriptions written, anticoagulation prescriptions written, and smoking cessation education being provided [23]. The gene discussed is PLAT; the disease is deep vein thrombosis.